SEC Comment Letter for iBio, Inc. (IBIO) (CIK 0001420720) (IBIO) — Sep 5, 2019
iBio, Inc. (IBIO) (CIK 0001420720)
Date: Sept. 5, 2019 · CIK: 0001420720 · Accession: 0000000000-19-013230
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233504
Letter
September 5, 2019 Robert B. Kay Chief Executive Officer iBio, Inc. 600 Madison Avenue, Suite 1601 New York, NY 10022-1737 Re:iBio, Inc. Registration Statement on Form S-1 Filed August 28, 2019 File No. 333-233504 Dear Mr. Kay: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Andrew Abramowitz, Esq.
Show Raw Text
September 5, 2019
Robert B. Kay
Chief Executive Officer
iBio, Inc.
600 Madison Avenue, Suite 1601
New York, NY 10022-1737
Re:iBio, Inc.
Registration Statement on Form S-1
Filed August 28, 2019
File No. 333-233504
Dear Mr. Kay:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Andrew Abramowitz, Esq.